Opko Health (NASDAQ:OPK) Sees Strong Trading Volume

Shares of Opko Health Inc. (NASDAQ:OPK) saw unusually-high trading volume on Monday . Approximately 17,857,400 shares were traded during trading, an increase of 299% from the previous session’s volume of 4,470,455 shares.The stock last traded at $2.13 and had previously closed at $2.10.

OPK has been the subject of a number of research analyst reports. ValuEngine raised Opko Health from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Barrington Research reissued a “buy” rating and set a $4.00 price target on shares of Opko Health in a research note on Thursday, September 12th. BidaskClub lowered Opko Health from a “hold” rating to a “sell” rating in a research note on Wednesday, October 16th. Finally, Zacks Investment Research raised Opko Health from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research note on Friday.

The company has a current ratio of 1.21, a quick ratio of 1.04 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.29 billion, a P/E ratio of -8.52 and a beta of 2.22. The stock has a 50 day moving average of $2.05 and a 200-day moving average of $2.10.

Opko Health (NASDAQ:OPK) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.01. Opko Health had a negative return on equity of 12.17% and a negative net margin of 26.55%. The firm had revenue of $226.40 million during the quarter, compared to analyst estimates of $225.07 million. During the same period last year, the company earned ($0.01) EPS. Opko Health’s quarterly revenue was down 14.1% compared to the same quarter last year. Research analysts anticipate that Opko Health Inc. will post -0.41 EPS for the current year.

Several hedge funds have recently modified their holdings of the stock. Nuveen Asset Management LLC bought a new stake in Opko Health during the 2nd quarter valued at $4,789,000. Asymmetry Capital Management L.P. bought a new stake in Opko Health during the 2nd quarter valued at $3,974,000. Marshall Wace LLP raised its position in Opko Health by 3,541.3% during the 1st quarter. Marshall Wace LLP now owns 1,452,176 shares of the biotechnology company’s stock valued at $3,099,000 after purchasing an additional 1,412,295 shares in the last quarter. BlackRock Inc. raised its position in Opko Health by 4.4% during the 2nd quarter. BlackRock Inc. now owns 31,520,785 shares of the biotechnology company’s stock valued at $76,910,000 after purchasing an additional 1,330,639 shares in the last quarter. Finally, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management raised its position in Opko Health by 98.4% during the 2nd quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 2,092,606 shares of the biotechnology company’s stock valued at $5,106,000 after purchasing an additional 1,037,669 shares in the last quarter. 24.55% of the stock is owned by hedge funds and other institutional investors.

Opko Health Company Profile (NASDAQ:OPK)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Recommended Story: How Do I Invest in Dividend Stocks

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.